您現在的位置 :

醫療團隊

專業的醫護人員，提供最佳的醫療服務

醫師介紹

  •

梁志明醫師

一般內科學、一般消化系統疾病診治、教師發展培育、病毒性肝炎診治、肝硬化肝衰竭診治、診斷性超音波、介入性超音波診治、消化性潰瘍疾病、胃腸蠕動疾病(胃食道逆流疾病,食道弛緩不能症)、胃幽門螺旋桿菌診治、內視鏡診治、內視鏡逆行性膽胰道攝影及治療、內視鏡超音波、發炎性腸疾病診治、小腸鏡、內視鏡抗逆流手術、高解析度食道壓力檢測、食道酸鹼值檢測
  • 國語,英語,閩南語,客語
  • 副教授
醫師網路掛號
直接點選進入醫師網路掛號畫面
醫師資歷
  • 現職
    • 高雄長庚紀念醫院 胃腸肝膽科系病房主任(2023.7)
    • 高雄長庚紀念醫院胃腸肝膽科系 副教授級主治醫師(2020.07)
    • 長庚大學兼任助理教授(2021.02)
    • 正修科技大學兼任副教授
    • 部定副教授
  • 學歷
    • 成功大學醫學系畢
    • 長庚大學臨床醫學研究所博士班進修中
  • 經歷
    • 高雄長庚紀念醫院內科部住院醫師
    • 高雄長庚紀念醫院胃腸膽科系研究員
    • 支援高雄市立民生醫院 (2018.10~2019.12)
  • 學會與認證
    • 台灣內科醫學會 內科專科醫師 及指導醫師
    • 台灣消化系醫學會 會員、消化系內科專科醫師及指導醫師
    • 台灣消化系內視鏡醫學會 會員、消化系內視鏡專科醫師及指導醫師
    • 台灣醫學教育學會一般醫學師資
    • 台灣消化系內視鏡學會膽胰治療性內視鏡認證醫師
  • 論文及期刊發表
    • Sou FM, Hsu CN, Chiu YC, Wu CK, Lu LS, Kuo CM, Chiu SM, Chuah SK, Yang YH, Liang CM*. ?The association between trajectory of serum cholesterol, statin dosage, and the risk of recurrent biliary stone diseases. J Formos Med Assoc. 2024 Apr 7:S0929-6646(24)00203-1. (SCI)

    • Tai WC, Wu IT, Wang HM, Huang PY, Yao CC, Wu CK, Yang SC, Liang CM*, Hsu PI, Chuah SK. The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan. J Microbiol Immunol Infect. 2024 Aug;57(4):601-608. (SCI)
      比較埃索美拉唑基礎和拉百樂唑基礎高劑量雙重療法在首線幽門螺旋桿菌的根除治療效果- 台灣多中心實際研究報告
    • Wang HM, Huang PY, Yang SC, Wu MK, Tai WC, Chen CH, Yao CC, Lu LS, Chuah SK, Lee YC*, Liang CM*. Correlation between Psychosomatic Assessment, Heart Rate Variability, and Refractory GERD: A Prospective Study in Patients with Acid Reflux Esophagitis. Life (Basel). 2023 Sep 3;13(9):1862. (SCI)
      身心評估、心率變異性與難治性胃食道逆流病的關聯性：在酸性逆流性食道炎患者中的前瞻性研究
    • Tai WC, Yang SC, Yao CC, Wu CK , Liu AC, Lee CH, Kuo YH, Chuah SK*, Liang CM*. The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naive Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial. Infect Dis Ther. 2023 May;12(5):1415-1427. (SCI)
      比較新的第一線幽門螺旋桿菌除菌治療效果—隨機試驗之台灣報告
    • Ma TL, Tai WC, Loke SS, Yao CC, Liang CM*, Chuah SK. Efficacy and Safety of 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Helicobacter pylori Eradication in the Elderly. Drugs Aging. 2023 Jan;40(1):71-79. (SCI)
      七日非鉍劑聯合四聯療法在老年人一線抗幽門螺桿菌治療中的療效和安全性
    • Liang CM, Chiu YC, Lu LS, Wu CK, Sou FM, Chiu SM, Lee YC, Huang PY, Chuah SK, Kuo CM*. Early and Direct Endoscopic Stone Removal in the Moderate Grade of Acute Cholangitis with Choledocholithiasis Was Safe and Effective: A Prospective Study. Life (Basel). 2022 Nov 30;12(12):2000. (SCI)
      對於中度急性膽管炎伴膽總管結石使用早期且直接內視鏡取石術是安全有效：一項前瞻性研究
    • Wu CK, Hsu CN, Cho WR, Yang SC, Liu AC, Tai WC, Lee CH, Yang YH, Chuah SK, Liang CM*. Increased Risk of Pyogenic Liver Abscess after Endoscopic Sphincterotomy for Treatment of Choledocholithiasis. Infect Drug Resist. 2021 Jun 8; 14:2121-2131. (SCI)
      總膽管結石經內視鏡逆行性膽胰管攝影術術後產生肝膿瘍的風險
    • Hung KT, Yang SC, Wu CK, Wang HM, Yao CC, Liang CM*, Tai WC, Wu KL, Kuo YH, Lee CH, Chuah SK*. Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice. Infect Drug Resist. 2021 Mar; 2021(14):1239-1246. (SCI)
      比較第一線不含BISMUTH的7天期幽門桿菌四合一療法，由ESOMEPRAZOLE或LANSOPRAZOLE當基底對於幽門桿菌清除率的影響
    • Hung KT, Kuo CM, Tsai CE, Chiu YC, Lu LS, Wu CK, Sou FM, Huang PY, Tai WC, Kuo CH, Liang CM*, Chuah SK. Single-stage retrograde endoscopic common bile duct stone removal might be sufficient in moderate acute cholangitis with a stone size ?12?mm: A retrospective cohort study with propensity score matching. Adv Dig Med. 2020 Dec;7(4):188–194. (台灣消化醫學雜誌)
      一階段逆行性內視鏡膽道取石術對於中度急性膽管炎併有膽管結石(石頭小於12公厘)的病患是足夠安全的-一個回溯性傾向分數分析研究
    • Liang CM, Tai WC, Hsu PI, Wu DC, Kuo CH, Tsay FW, Lee CL, Chen KY*, Chuah SK*. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therap Adv Gastroenterol . 2020 Dec 10;13:1756284820976990. (SCI)
      胃幽門螺旋桿菌抗藥性改變的趨勢 (2013-2019年): 台灣多中心的報告
    • Liang CM, Yang SC, Wu CK, Li YC, Yeh WS, Tai WC, Lee CH, Yang YH, Tsai TH, Hsu CN*, Chuah SK*. Risk of Recurrent Peptic Ulcer Disease in Patients Receiving Cumulative Defined Daily Dose of Nonsteroidal Anti-Inflammatory Drugs. J Clin Med. 2019 Oct; 8(10): 1722. (SCI)
      累積暴露量非類固醇止痛藥劑的使用導致消化性潰瘍疾病復發之危險因子
    • Yao CC, Kuo CM, Hsu CN, Yang SC, Wu CK, Tai WC, Liang CM*, Wu KL, Huang CF, Bi KW, Lee CH, Chuah SK. First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus. Infect Drug Resist. 2019 May 29;12:1425-1431. (SCI)
      第一線幽門螺旋桿菌的根除治療在糖尿病患有較差的治療效果
    • Liang CM, Kuo CM*, Lu LS, Wu CK, Tsai CE, Kuo MT, Chiu YC*, Tai WC, Kuo YH, Kuo CH, Chuah SK, Changchien CS. A comparison between non-sedation and general endotracheal anesthesia for retrograde endoscopic common bile duct stone removal: A tertiary center experience. Biomed J. 2019 Apr;42(2):131-136. (SCI)
      比較全身麻醉式與無麻醉式逆行性內視鏡膽道取石術:一個醫學中心的經驗
    • Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Yao CC, Tsai CE, Liang CM*, Wang YK, Wang JW, Huang CF, Chuah SK; Taiwan Acid-Related Disease Study Group. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial. Drug Des Devel Ther. 2019 Apr 26;13:1347-1356. (SCI)
      比較60 毫克DEXLANSOPRAZOLE 和 40 毫克ESOMEPRAZOLE 在輕度胃食道逆流症二十四周需要時服用的臨床療效：前瞻性隨機研究
    • Huang HT, Wang HM, Yang SC, Tai WC, Liang CM*, Wu KL, Lee CH, Chuah SK. Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication. Infect Drug Resist. 2018 Oct 30;11:2073-2080. (SCI)
      探討14天四合一藥劑在第三線幽門螺旋桿菌殺菌治療效果
    • Liang CM, Chiu CH, Wang HM, Tai WC, Yao CC,Tsai CE, Kuo CM, Chiu YC, Wu KL, Lee CH*, Tsai KL, Huang CF, Chuah SK*. First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan. Biomed Res Int. 2017;2017:3762194. (SCI)
      台灣慢性腎病患者感染胃幽門螺旋桿菌的第一線藥物治療
    • Liang CM(co-first), Kuo MT(co-first), Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK*, Taiwan Acid-Related Disease Study Group. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. World J Gastroenterol. 2017 Dec 21; 23(47): 8395-8404. (SCI)
      以dexlansoprazole 60 mg 及 esomeprazole 40 mg治療 A和B 級的 胃食道逆流病人的第一周臨床藥物治療效果
    • Liang CM, Hsu CN, Tai WC, Yang SC, Wu CK, Shih CW, Ku MK, Yuan LT, Wang JW, Tseng KL, Sun WC, Hung TH, Nguang SH, Hsu PI, Wu DC*, Chuah SK*; Taiwan Acid-Related Disease (TARD) Study Group. Risk factors influencing the outcome of peptic ulcer bleeding in chronic kidney disease after initial endoscopic hemostasis: A nationwide cohort study. Medicine (Baltimore). 2016 Sep;95(36):e4795. (SCI)
      影響慢性腎臟病患消化性潰瘍出血預後的因子-全國性世代研究
    • Chuah SK(co-first), Liang CM(co-first), Lee CH, Chiou SS, Chiu YC, Hu ML, Wu KL, Lu LS, Chou YP, Chang KC, Kuo CH, Kuo CM, Hu TH, Tai WC*. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication. Medicine (Baltimore). 2016 May;95(19):e3586. (SCI)
      比較兩種以LEVOFLOXACIN為基礎的幽門螺旋桿菌第二線治療之效益：隨機對照研究
    • Tai WC, Liang CM(co-first), Lee CH, Chiu CH, Hu ML, Lu LS, Kuo YH, Kuo CM, Yen YH, Kuo CH, Chiou SS, Wu KL, Chiu YC, Hu TH, Chuah SK*. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A” Success Rate for First-Line Helicobacter pylori Eradication. Biomed Res Int. 2015 Jan;2015:623732. (SCI)

    • Liang CM, Cheng JW(co-first), Kuo CM, Chang KC, Wu KL, Tai WC*, Chiu KW, Chiou SS, Lin MT, Hu TH, Chuah SK. Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice. Biomed J. 2014 Sep-Oct.37(5):326-330. 長庚醫誌
      七天含LEVOFLOXACIN三合一第二線幽門螺旋桿菌合適性:一個回朔性的台灣報告
    • Liang CM, Hu TH, Lu SN, Hung CH*, Huang CM, Wang JH, Yen YH, Chen CH, Chang KC, Tsai MC, Kuo YH, Lee CM. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy. J Viral Hepat. 2013 Nov.; 20(11):761-769. (SCI)
      C型肝炎病毒變異與介白質28基因多形性於長效型干擾素合併RIBAVIRIN治療療效之相關性:一前瞻性研究
    • Liang CM, Chiu YC, Wu KL*, Tam W, Tai WC, Hu ML, Chou YP, Chiu KW, Chuah SK. Impact factors for difficult cecal intubation during colonoscopy. Surg Laparosc Endosc Percutan Tech. 2012 Oct;22(5):443-6. (SCI)
      完成困難大腸鏡檢查的影響因素
    • Liang CM, Lee JH (co-first), Kuo YH, Wu KL, Chiu YC, Chou YP, Hu ML, Tai WC, Chiu KW, Hu TH, Chuah SK*. Intravenous non-high-dose pantoprazole is equally effective as high-dose pantoprazole in preventing rebleeding among low risk patients with a bleeding peptic ulcer after initial endoscopic hemostasis. BMC Gastroenterol. 2012 Mar 28;12:28. (SCI)
      低風險的消化系潰瘍出血病人經內視鏡止血治療後使用非高劑量和高劑量靜脈注射PANTOPRAZOLE具有相同的預防再出血效果
    • Liang CM, Wu KL, Chou YP, Tai WC*, Chiu YC, Changchien CS, Chiou SS, Hu TH, Chuah SK. Prevalence and Associated Factors of Hyperechoic Pancreas on Sonography. Gastroenterol J Taiwan. 2011 Sept; 28(3): 281-288.
      高超音波回音胰的盛行率及其相關因子
    • Liang CM, Wang MC, Chen YJ, Hung CH*, Hu TH. Primary Duodenal Mucosa-Associated Lymphoid Tissue Lymphoma: Report of a Case. Gastroenterol J Taiwan 2011 Sept; 28(3):310-316.
      原發性十二指腸黏膜相關淋巴組織淋巴瘤：一病例報告